Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)

Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO).

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00738855

Enrollment

100

Registered

2008-08-21

Start date

2006-02-28

Completion date

2008-01-31

Last updated

2008-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Bowel Obstruction

Keywords

Adhesions, Oral contrast, Exploration

Brief summary

Mini abstract : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups. Eight episodes in eight patients were excluded. Gastrografin group showed a significant decrease of both the time between admission and operation and that of hospital stay .The need for surgery was reduced but statistically insignificant.

Detailed description

Abstract Background: Many published studies have shown that Gastrografin can be used for diagnosis post operative acute small bowel obstruction (ASBO) and assessing the need for surgical intervention .However,the studies have reported conflicting results hence the aim of our study to test this hypothesis. Patients and methods : Altogether 100 patients with 117 episodes of ASBO were randomized into control and gastrografin groups in a double blinded fashion. Eight episodes in eight patients were excluded due to protocol violation. In Gastrografin group,100 ml of the dye administered through a nasogastric tube and complete obstruction has been considered if the contrast failed to reach the colon on the 24-hour film. Patients were operated on only if they developed signs of strangulation or failed to improve within 48 hours.

Interventions

OTHEROral Gastrografin

100 ml of the dye administered through a nasogastric tube

OTHERNothing per os

A nasogastric tube

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients admitted to our surgical department by postoperative SBO were considered for inclusion in this trial.

Exclusion criteria

* Age less than 18 years * Large bowel obstruction * Recent (within 4 weeks) abdominal surgery * Ileus * Cancer peritonitis * Peritonitis * Strangulation symptoms and signs * Obstructed abdominal wall or groin hernia * Subtotal or total colectomy * All patients in whom the final diagnosis was not SBO

Design outcomes

Primary

Measure	Time frame
resolving	48 hours

Secondary

Measure	Time frame
non resolving	48 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026